FDA

mechanical gears shifting

Biotech

Adaptimmune's cell therapy hits key goal in pivotal sarcoma test

Adaptimmune is prepping for another FDA submission after its cell therapy was tied to a 42% response rate in a phase 2 sarcoma trial.

Gabrielle Masson Nov 13, 2024 2:57pm

An artists impression of DNA The DNA appears to be made up of glowing orbs and appears on a blue background

FDA approves Caris multi-cancer companion diagnostic test

Nov 13, 2024 9:00am

Johnson Johnson

J&J gets FDA OK to begin trials for its Ottava surgical robot

Nov 12, 2024 1:45pm

silhouette of virtual human and nebula cosmos

Zeta Surgical to roll out brain surgery navigation system

Nov 11, 2024 11:00am

JNJ Varipulse system

FDA approves J&J’s Varipulse pulsed field ablation system

Nov 7, 2024 3:00pm

eyeball retinal diseases

FDA clears first treatment for dry AMD, with LumiThera's Valeda

Nov 6, 2024 10:30am